The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type IDH1 cholangiocarcinoma before availability of mIDH1 inhibitors

ESMO Gastrointestinal Oncology · Elsevier

Аннотация

Publication date: September 2026 Source: ESMO Gastrointestinal Oncology, Volume 13, Part B Author(s): V. Sahai, J.W. Valle, N. Fares, M. Javle, I. Ghanem, P. Cerdà, I.G. Rapposelli, I.G. Jimenez, M.A. Gonzalez-Carmona, A. Hollebecque, R. Pazo Cid, D.H. Palmer, R. Vera, A. Casadei-Gardini, D. Melisi, J.-F. Blanc, L. Perkhofer, A. Lamarca, H. Gharbi, V. Manuel-Minguez

Читать у издателя →

Похожие статьи